Reviews Estradiol Vaginal Cream


No reviews yet.

Estrace Vaginal Cream Drug Description
ESTRACE® CREAM
(estradiol) Vaginal Cream, USP, 0.01%

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens results in a different endometrial risk profile than
synthetic estrogens at equivalent estrogen doses. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone
acetate relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women or to women taking estrogen-alone therapy. (See
CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol (Estrace Vaginal Cream, Estring)?

Estradiol increases the risk of developing a condition (endometrial hyperplasia) that may lead to cancer of the lining of the uterus. Taking progestins, another hormone drug, while using estradiol lowers the risk of developing this condition. Therefore, if your uterus has not been removed, your doctor may prescribe a progestin for you to take together while using estradiol. Visit your doctor regularly and report any unusual vaginal bleeding right away.
Treatment with estradiol long-term...
Read All Potential Side Effects for Estrace Vaginal Cream »




Each gram of ESTRACE® (estradiol vaginal cream, USP, 0.01%) contains 0.1
mg estradiol in a nonliquefying base containing purified water, propylene glycol,
stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208
(4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and tertiary-butylhydroquinone.
Estradiol is chemically described as estra-1,3,5(10)-triene-3,17β-diol.
It has an empirical formula of C18H24O2 and
molecular weight of 272.37. The structural formula is:







Last reviewed on RxList: 3/31/2009




Estrace Vaginal Cream Drug Description
ESTRACE® CREAM
(estradiol) Vaginal Cream, USP, 0.01%

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens results in a different endometrial risk profile than
synthetic estrogens at equivalent estrogen doses. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone
acetate relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women or to women taking estrogen-alone therapy. (See
CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol (Estrace Vaginal Cream, Estring)?

Estradiol increases the risk of developing a condition (endometrial hyperplasia) that may lead to cancer of the lining of the uterus. Taking progestins, another hormone drug, while using estradiol lowers the risk of developing this condition. Therefore, if your uterus has not been removed, your doctor may prescribe a progestin for you to take together while using estradiol. Visit your doctor regularly and report any unusual vaginal bleeding right away.
Treatment with estradiol long-term...
Read All Potential Side Effects for Estrace Vaginal Cream »




Each gram of ESTRACE® (estradiol vaginal cream, USP, 0.01%) contains 0.1
mg estradiol in a nonliquefying base containing purified water, propylene glycol,
stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208
(4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and tertiary-butylhydroquinone.
Estradiol is chemically described as estra-1,3,5(10)-triene-3,17β-diol.
It has an empirical formula of C18H24O2 and
molecular weight of 272.37. The structural formula is:







Last reviewed on RxList: 3/31/2009




Estrace Vaginal Cream Drug Description
ESTRACE® CREAM
(estradiol) Vaginal Cream, USP, 0.01%

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens results in a different endometrial risk profile than
synthetic estrogens at equivalent estrogen doses. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone
acetate relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women or to women taking estrogen-alone therapy. (See
CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol (Estrace Vaginal Cream, Estring)?

Estradiol increases the risk of developing a condition (endometrial hyperplasia) that may lead to cancer of the lining of the uterus. Taking progestins, another hormone drug, while using estradiol lowers the risk of developing this condition. Therefore, if your uterus has not been removed, your doctor may prescribe a progestin for you to take together while using estradiol. Visit your doctor regularly and report any unusual vaginal bleeding right away.
Treatment with estradiol long-term...
Read All Potential Side Effects for Estrace Vaginal Cream »




Each gram of ESTRACE® (estradiol vaginal cream, USP, 0.01%) contains 0.1
mg estradiol in a nonliquefying base containing purified water, propylene glycol,
stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208
(4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and tertiary-butylhydroquinone.
Estradiol is chemically described as estra-1,3,5(10)-triene-3,17β-diol.
It has an empirical formula of C18H24O2 and
molecular weight of 272.37. The structural formula is:







Last reviewed on RxList: 3/31/2009




Estrace Vaginal Cream Drug Description
ESTRACE® CREAM
(estradiol) Vaginal Cream, USP, 0.01%

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens results in a different endometrial risk profile than
synthetic estrogens at equivalent estrogen doses. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone
acetate relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women or to women taking estrogen-alone therapy. (See
CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol (Estrace Vaginal Cream, Estring)?

Estradiol increases the risk of developing a condition (endometrial hyperplasia) that may lead to cancer of the lining of the uterus. Taking progestins, another hormone drug, while using estradiol lowers the risk of developing this condition. Therefore, if your uterus has not been removed, your doctor may prescribe a progestin for you to take together while using estradiol. Visit your doctor regularly and report any unusual vaginal bleeding right away.
Treatment with estradiol long-term...
Read All Potential Side Effects for Estrace Vaginal Cream »




Each gram of ESTRACE® (estradiol vaginal cream, USP, 0.01%) contains 0.1
mg estradiol in a nonliquefying base containing purified water, propylene glycol,
stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208
(4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and tertiary-butylhydroquinone.
Estradiol is chemically described as estra-1,3,5(10)-triene-3,17β-diol.
It has an empirical formula of C18H24O2 and
molecular weight of 272.37. The structural formula is:







Last reviewed on RxList: 3/31/2009




Estrace Vaginal Cream Drug Description
ESTRACE® CREAM
(estradiol) Vaginal Cream, USP, 0.01%

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens results in a different endometrial risk profile than
synthetic estrogens at equivalent estrogen doses. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone
acetate relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women or to women taking estrogen-alone therapy. (See
CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol (Estrace Vaginal Cream, Estring)?

Estradiol increases the risk of developing a condition (endometrial hyperplasia) that may lead to cancer of the lining of the uterus. Taking progestins, another hormone drug, while using estradiol lowers the risk of developing this condition. Therefore, if your uterus has not been removed, your doctor may prescribe a progestin for you to take together while using estradiol. Visit your doctor regularly and report any unusual vaginal bleeding right away.
Treatment with estradiol long-term...
Read All Potential Side Effects for Estrace Vaginal Cream »




Each gram of ESTRACE® (estradiol vaginal cream, USP, 0.01%) contains 0.1
mg estradiol in a nonliquefying base containing purified water, propylene glycol,
stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208
(4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and tertiary-butylhydroquinone.
Estradiol is chemically described as estra-1,3,5(10)-triene-3,17β-diol.
It has an empirical formula of C18H24O2 and
molecular weight of 272.37. The structural formula is:







Last reviewed on RxList: 3/31/2009





Other reviews about Estradiol Vaginal Cream on wordpress

Ask Dr. Pat: Pain During Intercourse
  by nichirei
Have a question about women's health or menopause? Dr. Patricia Yarberry Allen may have the answer. Click here to send in your question to be posted on WVFC. by […]


Hormone Case Presentations
  by labrixco
Progesterone Deficiency/Estrogen Dominance: Mrs. J.T., a 45 year old woman with regular menstrual cycles complained of tender breasts, headaches and bloating (fluid retention) for two years just before […]


Ask Dr. Pat: Sex and the Safety of Vagifem
  by nichirei
Have a question about women's health or menopause? Dr. Patricia Yarberry Allen may have the answer. Click here to send in your question to be posted on WVFC. Question: […]


WHY NOT USE BENEFICIAL POSTMENOPAUSAL HORMONE REPLACEMENT HRT THAT AVOIDS PERIODS AND BREAST TENDERNESS?
  by healthspanlife
The new paper  this week from the WISDOM trial (stopped prematurely  in Oct 2002 as a result of the  precipitous closure of the main premarin-provera prempro arm of the […]


FDA Approved Bioidentical Hormones
  by bodylogicmd
We've mentioned that the FDA has approved over 20 bioidentical hormones and now want to share some of the hormones on that list, specifically those meant to treat […]


THE MOST IMPORTANT RCT IN HALF A CENTURY ON APPROPRIATE USE OF HRT IN WOMEN: Conjugated Oral Versus Transdermal Estrogen Replacement
  by healthspanlife
Nabhan ea at Indiana University have just published perhaps the most important randomized controlled trial RCT in half a century on physiological benefits and pitfalls […]


You should use the normal method of birth control …
  by saleemasraf
You should use the normal method of birth control (e.g., latex condoms and spermicidal foam or gel)tablets are having serious side effects. and never go for permanent birth […]


Awareness Into Action: Vaginal Estrogen Creams
  by DrKTRuddy
Many of my patients whose gynecologists have given them vaginal estrogen creams have been told by these doctors that there is little or no absorption of the estrogen […]


Menopause:Your Questions and Answers Here
  by someonehelpedme
  Menopause is the transition period in a woman's life when her ovaries stop producing eggs, her body produces less estrogen and progesterone, and menstruation becomes less frequent, eventually […]


He did enter Doctor Hadleys off
  by bkwjsfswcnsviog
_ ACT I _Ten thousand years have passed, and it is the time of the early voyaging from Europe […]



Other reviews about Estradiol Vaginal Cream on web:

Learn about the prescription medication Estrace Vaginal Cream (Estradiol Vaginal Cream), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Estrace Vaginal Cream (Estradiol Vaginal Cream) Drug Information ...


Estradiol vaginal cream To return to the main entry click here . What is estrogen vaginal cream? ESTRADIOL (Estrace®) vaginal cream contains a Estradiol vaginal cream: Information from Answers.com


Contact your doctor if vaginal discomfort occurs or if you suspect you have developed an infection while taking Estradiol Cream. Follow your doctor's instructions for examining your ... Estradiol Cream Facts and Comparisons at Drugs.com


Estradiol Vaginal cream To return to the main entry click here . What is this medicine? ESTRADIOL (es tra DYE ole) contains the female hormone Estradiol Vaginal cream: Information from Answers.com


Estradiol vaginal cream, USP, 0.01% Typical use. One gram is applied to the vagina nightly for 7 nights (sometimes 10 nights for ... Natural treatments for vaginal dryness — including estriol ...


Physician reviewed Estrace Vaginal Cream (topical) patient information - includes Estrace Vaginal Cream description, dosage and directions. Estrace Vaginal Cream (estradiol topical) medical facts from Drugs.com


Estradiol vaginal cream is a prescription medicine approved for treating vaginal menopause symptoms. This eMedTV article further explains what estradiol vaginal cream is used for ... Estradiol Vaginal Cream


Estradiol (a form of estrogen) is a female sex hormone necessary for many processes in the body. Estradiol vaginal products release estrogen that is absorbed directly through ... Estrace Vaginal Cream Information - Drugs and Treatments - MedHelp


Another larger randomized study comparing the estradiol vaginal ring (Estring) and estriol cream showed no difference in adverse effects (Barentsen, van de Weijer, & Schram, 1997). Estrogen and Its Effect on Vaginal Atrophy in Post-Menopausal ...


Estradiol Vaginal cream What is this medicine? ESTRADIOL (es tra DYE ole) contains the female hormone estrogen. It is used for symptoms of menopause, like vaginal dryness and ... Estradiol





Featured Reviews

Reviews Nateglinide

Starlix Drug Description Starlix® (nateglinide) Tablets DRUG DESCRIPTION What are the possible side effects of nateglinide (Starlix)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Altretamine

Hexalen Drug Description HEXALEN® (altretamine) Capsules 50 mg WARNINGS HEXALEN® capsules should only be given under the supervision of a physician experienced in the use of antineoplastic agents. Peripheral...
Read More  |  Review This
Reviews Alglucosidase Alfa

Lumizyme Drug Description LUMIZYME (alglucosidase alfa) for Injection, for Intravenous Use WARNING Life-threatening anaphylactic reactions, severe allergic reactions and immune mediated reactions have been observed in some patients...
Read More  |  Review This
Reviews Indigotindisulfonate

Indigo Carmine Drug Description INDIGO CARMINE (indigotindisulfonate sodium) Injection, USP DRUG DESCRIPTION Each 5 mL contains: 40 mg of Indigotindisulfonate Sodium, in Water for Injection, q.s. pH adjusted, when necessary, with Citric...
Read More  |  Review This
Reviews Nitrostat

Nitrostat Drug Description Nitrostat® (nitroglycerin) Tablets, USP DRUG DESCRIPTION What are the possible side effects of nitroglycerin (Nitrolingual, Nitrolingual Duo Pack, Nitroquick, Nitrostat)? Get emergency medical help...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....